Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation-Reference-Cited by-同舟云学术

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation

Published:2021-09 Issue:5 Volume:20 Page:865-875
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Oren Yifat S.^ORCID,Irony-Tur Sinai Michal,Golec Anita,Barchad-Avitzur Ofra,Mutyam Venkateshwar,Li Yao^ORCID,Hong Jeong^ORCID,Ozeri-Galai Efrat^ORCID,Hatton Aurélie,Leibson Chen,Carmel Liran^ORCID,Reiter Joel^ORCID,Sorscher Eric J.,Wilton Steve D.,Kerem Eitan,Rowe Steven M.^ORCID,Sermet-Gaudelus Isabelle,Kerem Batsheva

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference55 articles.

1. Cystic fibrosis;Rowe;N Engl J Med,2005

2. The future of cystic fibrosis care: a global perspective;Bell;Lancet Respir Med,2020

3. Alternative splicing in disease and therapy;Garcia-Blanco;Nat Biotechnol,2004

4. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy;Kerem;Pediatr Pulmonol,2005

5. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C → T mutation;Augarten;Lancet,1993

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa;Proceedings of the National Academy of Sciences;2024-08-19

2. Upregulation of a nonsense mediated decay (NMD) insensitive CFTR mRNA isoform has therapeutic potential for the treatment of 3’ CFTR PTC variants;2024-07-03

3. A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines;Advanced Drug Delivery Reviews;2024-06

4. Cystic fibrosis management in pediatric population—from clinical features to personalized therapy;Frontiers in Pediatrics;2024-05-10

5. Zukunft der Mukoviszidoseforschung und -therapie;Monatsschrift Kinderheilkunde;2024-04-08